Cargando…

Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan

Background and aims: We aimed to compare clinical outcomes and safety after sorafenib therapy between patients with Barcelona Clinic Liver Cancer (BCLC) stage B or C hepatocellular carcinoma (HCC) aged ≥75 years (aged group, n=179) and those with BCLC stage B or C HCC aged <75 years (control grou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishikawa, Hiroki, Takeda, Haruhiko, Tsuchiya, Kaoru, Joko, Kouji, Ogawa, Chikara, Taniguchi, Hiroyoshi, Orito, Etsuro, Uchida, Yasushi, Osaki, Yukio, Izumi, Namiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067509/ https://www.ncbi.nlm.nih.gov/pubmed/24963354 http://dx.doi.org/10.7150/jca.9257

Ejemplares similares

Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib
por: Sakai, Kazuko, et al.
Publicado: (2015)

Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases
por: Takeda, Haruhiko, et al.
Publicado: (2012)

Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma
por: NISHIKAWA, HIROKI, et al.
Publicado: (2012)

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
por: Liu, Kai-Cai, et al.
Publicado: (2020)

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
por: Wu, Fei-Xiang, et al.
Publicado: (2017)

Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection
por: Fujii, Hideki, et al.
Publicado: (2022)

Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
por: Itakura, Jun, et al.
Publicado: (2016)

Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study
por: Yasui, Yutaka, et al.
Publicado: (2022)

Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice
por: Lee, I-Cheng, et al.
Publicado: (2015)

Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy
por: Saeki, Issei, et al.
Publicado: (2023)

The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study
por: Tsuchiya, Kaoru, et al.
Publicado: (2021)

Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review
por: Osaki, Yukio, et al.
Publicado: (2015)

Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group
por: Mashiba, Toshie, et al.
Publicado: (2018)

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
por: Arizumi, Tadaaki, et al.
Publicado: (2014)

Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan
por: Nishikawa, Hiroki, et al.
Publicado: (2012)

Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma
por: Takada, Hitomi, et al.
Publicado: (2018)

Clinical Significance of Occult Hepatitis B Infection in Progression of Liver Disease and Carcinogenesis
por: Nishikawa, Hiroki, et al.
Publicado: (2013)

Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis
por: Nishikawa, Hiroki, et al.
Publicado: (2015)

Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis
por: Nishikawa, Hiroki, et al.
Publicado: (2017)

Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma
por: Nojiri, Shunsuke, et al.
Publicado: (2012)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
por: Nishikawa, Hiroki, et al.
Publicado: (2014)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Extending Surgical Resection for Hepatocellular Carcinoma Beyond Barcelona Clinic for Liver Cancer (BCLC) Stage A: A Novel Application of the Modified BCLC Staging System
por: Wee, Ian J Y, et al.
Publicado: (2022)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
por: Sekiguchi, Shuhei, et al.
Publicado: (2022)

Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score
por: Kaneko, Shun, et al.
Publicado: (2020)

Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review
por: Nishikawa, Hiroki, et al.
Publicado: (2013)

Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C
por: Itakura, Jun, et al.
Publicado: (2020)

A new model to estimate duration of survival in patients with hepatocellular carcinoma with BCLC intermediate stage
por: Ninomiya, Masashi, et al.
Publicado: (2023)

A Case of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Refractory to Epirubicin That Showed Marked Decrease in Tumor Markers after Transcatheter Arterial Infusion with Miriplatin
por: Nishikawa, Hiroki, et al.
Publicado: (2010)

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma
por: Tsuchiya, Kaoru, et al.
Publicado: (2014)

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
por: Takada, Hitomi, et al.
Publicado: (2019)

Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification
por: Kamiyama, Toshiya, et al.
Publicado: (2017)

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma
por: Kim, Jun Young, et al.
Publicado: (2016)

Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage
por: Kikuchi, Luciana, et al.
Publicado: (2017)

Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag
por: Brown, Robert S., et al.
Publicado: (2021)

Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus
por: Tamaki, Nobuharu, et al.
Publicado: (2021)

Real‐world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group
por: Mashiba, Toshie, et al.
Publicado: (2019)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6o4buld7voghpafj51s3hits6s